Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) has announced that, based upon a preliminary vote assessment, shareholders have elected all six of the Company’s nominees to the Board of Directors at the Annual Meeting of Shareholders held on June 21, 2023. The Company notes that quorum was present at the Annual Meeting and that the number of shares represented at the Meeting exceeded 40% of the Company’s outstanding shares entitled to vote.
In a significant change from all prior universal proxy contests, broker discretionary authority was retained for the routine auditor proposal with respect to all MindMed shareholders who did not receive proxy materials from the contesting shareholder.
Latham & Watkins LLP represents MindMed in connection with the proxy contest by FCM with a shareholder activism and takeover defense team led by Chicago partner Christopher Drewry, Global Co-Chair of Latham’s Shareholder Activism & Takeover Defense Practice, New York partner Ian Nussbaum, and Washington, D.C. partner Michele Anderson, with associates Jeremie Ruiz and Henna Jalal. Advice was also provided on NASDAQ matters by New York counsel Gail Neely and on securities litigation matters by San Diego partner Colleen Smith.